Total Payments
$480,702
2024 Payments
$532.98
Companies
18
Transactions
490
Medicare Patients
7,333
Medicare Billing
$1.6M
Payment Breakdown by Category
Other$332,229 (69.1%)
Consulting$59,893 (12.5%)
Travel$52,852 (11.0%)
Research$24,908 (5.2%)
Food & Beverage$10,735 (2.2%)
Education$83.55 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $325,704 | 112 | 67.8% |
| Consulting Fee | $59,893 | 34 | 12.5% |
| Travel and Lodging | $52,852 | 188 | 11.0% |
| Unspecified | $24,908 | 16 | 5.2% |
| Food and Beverage | $10,735 | 127 | 2.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,275 | 1 | 1.1% |
| Honoraria | $1,250 | 1 | 0.3% |
| Education | $83.55 | 11 | 0.0% |
Payments by Type
General
$455,793
474 transactions
Research
$24,908
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $170,958 | 173 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $65,862 | 70 | $0 (2023) |
| Daiichi Sankyo Inc. | $60,824 | 62 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $46,891 | 57 | $0 (2022) |
| Genentech USA, Inc. | $41,792 | 38 | $0 (2019) |
| Seagen Inc. | $28,318 | 20 | $0 (2022) |
| Gilead Sciences, Inc. | $23,817 | 19 | $0 (2024) |
| PFIZER INC. | $23,376 | 22 | $0 (2023) |
| Eli Lilly and Company | $10,938 | 5 | $0 (2022) |
| F. Hoffmann-La Roche AG | $3,014 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $532.98 | 6 | Gilead Sciences, Inc. ($187.22) |
| 2023 | $30,012 | 24 | Gilead Sciences, Inc. ($13,966) |
| 2022 | $52,576 | 54 | Daiichi Sankyo Inc. ($29,801) |
| 2021 | $70,965 | 64 | Daiichi Sankyo Inc. ($24,241) |
| 2020 | $38,428 | 40 | AstraZeneca Pharmaceuticals LP ($11,419) |
| 2019 | $22,902 | 30 | Puma Biotechnology, Inc. ($10,585) |
| 2018 | $164,918 | 170 | Novartis Pharmaceuticals Corporation ($103,542) |
| 2017 | $100,368 | 102 | Novartis Pharmaceuticals Corporation ($64,704) |
All Payment Transactions
490 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $106.45 | General |
| Category: ONC | ||||||
| 06/03/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $80.77 | General |
| Category: ONC | ||||||
| 05/31/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $79.00 | General |
| 05/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $119.76 | General |
| Category: Oncology | ||||||
| 03/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $132.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 11/10/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 11/08/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $832.50 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 09/13/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $125.94 | General |
| Category: Oncology | ||||||
| 08/28/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $68.00 | General |
| Category: ONC | ||||||
| 08/10/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,740.00 | General |
| Category: ONC | ||||||
| 08/05/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $1,467.78 | General |
| Category: ONC | ||||||
| 08/05/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $701.81 | General |
| Category: ONC | ||||||
| 08/05/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $382.91 | General |
| Category: ONC | ||||||
| 08/05/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $108.16 | General |
| 08/02/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,450.00 | General |
| Category: Oncology | ||||||
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Travel and Lodging | In-kind items and services | $293.00 | General |
| Category: Oncology | ||||||
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Travel and Lodging | In-kind items and services | $273.46 | General |
| Category: Oncology | ||||||
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $103.42 | General |
| Category: Oncology | ||||||
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Travel and Lodging | In-kind items and services | $67.95 | General |
| Category: Oncology | ||||||
| 06/09/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 06/07/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $109.07 | General |
| Category: Oncology | ||||||
| 04/11/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,380.00 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $12,700 | 9 |
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $9,468 | 3 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $1,471 | 2 |
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 1,778 | 49,330 | $2.6M | $511,794 |
| 2022 | 47 | 1,898 | 58,702 | $2.4M | $439,026 |
| 2021 | 51 | 2,017 | 56,258 | $2.2M | $375,610 |
| 2020 | 44 | 1,640 | 52,932 | $1.5M | $235,893 |
Total Patients
7,333
Total Services
217,222
Medicare Billing
$1.6M
Procedure Codes
190
All Medicare Procedures & Services
190 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 7,000 | $1.0M | $303,315 | 29.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 31 | 34 | $119,816 | $42,126 | 35.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 25 | 17,100 | $359,100 | $40,656 | 11.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 236 | $77,985 | $20,432 | 26.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 70 | 133 | $88,578 | $14,235 | 16.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 99 | $46,040 | $13,756 | 29.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 29 | 32 | $17,600 | $8,788 | 49.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 21 | 62 | $244,156 | $8,182 | 3.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 20 | 12,750 | $76,500 | $5,040 | 6.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 68 | $15,980 | $4,077 | 25.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 64 | 76 | $22,420 | $3,718 | 16.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 126 | 354 | $21,240 | $3,648 | 17.2% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 11 | 50 | $3,500 | $3,489 | 99.7% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 76 | 163 | $19,560 | $3,292 | 16.8% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 78 | 173 | $16,089 | $3,186 | 19.8% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 16 | 17 | $17,102 | $3,014 | 17.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 127 | 397 | $13,498 | $3,010 | 22.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 119 | 356 | $6,408 | $2,957 | 46.1% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 11 | 330 | $86,460 | $2,459 | 2.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $8,806 | $2,237 | 25.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 61 | 178 | $18,156 | $2,170 | 12.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 39 | $12,636 | $2,121 | 16.8% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 28 | 163 | $8,476 | $1,485 | 17.5% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 13 | 18 | $5,724 | $1,406 | 24.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 30 | 54 | $7,398 | $1,391 | 18.8% |
About Dr. Jay Andersen, M.D
Dr. Jay Andersen, M.D is a Hematology & Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922001023.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Andersen, M.D has received a total of $480,702 in payments from pharmaceutical and medical device companies, with $532.98 received in 2024. These payments were reported across 490 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($325,704).
As a Medicare-enrolled provider, Andersen has provided services to 7,333 Medicare beneficiaries, totaling 217,222 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 190 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Portland, OR
- Active Since 05/23/2005
- Last Updated 12/22/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1922001023
Products in Payments
- KISQALI (Drug) $168,189
- Nerlynx (Drug) $33,833
- Perjeta (Biological) $33,170
- Enhertu (Drug) $31,023
- ENHERTU (Drug) $29,801
- TUKYSA (Drug) $28,318
- FASLODEX (Drug) $25,927
- Trodelvy (Drug) $23,697
- ENHERTU (Biological) $17,372
- NERLYNX (Drug) $13,058
- TALZENNA (Drug) $12,700
- Herceptin (Biological) $6,599
- LYNPARZA (Drug) $4,348
- IBRANCE (Drug) $3,551
- Oral Paclitaxel (Drug) $2,750
- PIQRAY (Drug) $2,649
- Non-Covered Product (Drug) $1,896
- Kadcyla (Biological) $333.00
- KEYTRUDA (Biological) $168.28
- Orserdu (Drug) $119.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Portland
Brian Druker, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Rachel Sanborn, Md, MD
Hematology & Oncology — Payments: $322,427
Hematology & Oncology $322,427
Richard Maziarz, Md, MD
Hematology & Oncology — Payments: $246,109
Hematology & Oncology $246,109
Tibor Kovacsovics, Md, MD
Hematology & Oncology — Payments: $245,023
Hematology & Oncology $245,023
John Godwin, Md, MD
Hematology & Oncology — Payments: $96,623
Hematology & Oncology $96,623
Dr. Rom Leidner, Md, MD
Hematology & Oncology — Payments: $79,796
Hematology & Oncology $79,796